Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI
Open access

Cardiovascular Risk in BRCA1/2 Mutation Carriers: A Matched Cohort Study of Breast Cancer Survivors

M. D. Manshadi N. Manouchehri L. Hübbert A. Liljegren A. Manouchehrinia C. Linder-stragliotto J. Rantala E. Hedayati N. Kiani
Jul 2026 · medRxiv · 0 citations
Medicine

TL;DR

BRCA-BC did not demonstrate increased cardiovascular risk after BC diagnosis, and the apparent inverse association with CVD likely reflects the high incidence of competing risks, which limit the window for CVD to manifest.

DOI Semantic Scholar
Read PDF

Similar papers

Open access Sep 2026

Divergent Prognostic Impact of Germline BRCA1 and BRCA2 Variants in Non-Metastatic Breast Cancer: A Real-World Cohort Study

Background: Germline pathogenic variants in BRCA1 and BRCA2 are established contributors to hereditary breast cancer, yet their separate prognostic effects in non-metastatic disease remain uncertain because they are frequently analyzed as a single group. Methods: We retrospectively evaluated 360 patients with stage I–I...

İ. Bayrakçı, R. Coşar, N. Sut et al. · 0 citations
Open access Oct 2026

BRCA1/2 Carriers With Breast-Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes.

Germline pathogenic variants in BRCA1/2 substantially increase lifetime risks of both breast and ovarian cancers. However, whether specific mutation characteristics predispose carriers to breast-ovarian double primary cancers (DPC) and whether DPC affects ovarian cancer outcomes-particularly in the PARP inhibitor (PARP...

Tong-Xia Wang, Dan Zhao, Yue-Lin Song et al. · 0 citations
Open access Sep 2026

Development and Validation of a Competing-Risk Nomogram for Predicting Breast Cancer–Specific Survival in Young Women with Early-Stage Breast Cancer: A SEER-Based Study

Background & Objective: Breast cancer in women aged ≤40 years is biologically aggressive and carries a disproportionate cancer-specific mortality risk. Existing prognostic tools predominantly predict overall survival, rarely account for competing risks of non-cancer death, and have not evaluated whether primary treatme...

Umema Tariq, Yousaf Ali, Mohammad Idrees et al. · 0 citations
Open access Oct 2026

PROGNOSTIC RISK SCALE FOR MORTALITY IN BREAST CANCER

Relevance: Breast cancer is the most common malignancy in women and one of the leading causes of cancer-related mortality. Despite the availability of clinical and biological prognostic factors, developing simple, clinically applicable risk stratification tools remains an important challenge. The study aimed to iden...

I. Novikov, S. Yessentayeva, V. Makarov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.